Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA.
Arch Pathol Lab Med. 2013 Jun;137(6):865-70. doi: 10.5858/arpa.2012-0104-RS.
B-cell lymphomas, such as low-grade follicular lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma, can transform to histiocytic/dendritic cell sarcoma (H/DS) in rare cases. The diagnosis of this unconventional neoplastic evolution relies on a combination of immunophenotypic analysis and genotypic studies. A genotype identical to that of the primary B-cell neoplasm in a secondary neoplasm with H/DS immunophenotype supports the lineage conversion to H/DS. Putative mechanisms for this unusual phenomenon include dedifferentiation, common immature progenitor, and transdifferentiation models, the latter of which is suggested by clinical laboratory data at the present time. Elucidation of the molecular mechanisms governing this lineage conversion may facilitate the understanding of carcinogenesis of not only hematopoietic but also nonhematolymphoid neoplasms. The clinical outcome of secondary H/DS is dismal, as observed in sporadic cases, and the optimal treatment remains to be determined.
B 细胞淋巴瘤,如低级别滤泡性淋巴瘤和慢性淋巴细胞白血病/小淋巴细胞淋巴瘤,在极少数情况下可转化为组织细胞/树突状细胞肉瘤(H/DS)。这种非传统肿瘤演变的诊断依赖于免疫表型分析和基因型研究的结合。在具有 H/DS 免疫表型的继发性肿瘤中,如果其基因型与原发性 B 细胞肿瘤完全一致,则支持向 H/DS 的谱系转化。这种异常现象的潜在机制包括去分化、共同幼稚祖细胞和转分化模型,目前临床实验室数据提示后者。阐明控制这种谱系转化的分子机制可能有助于理解不仅是造血系统而且是非造血淋巴系统肿瘤的癌变。如散发性病例所见,继发性 H/DS 的临床结局较差,最佳治疗方法仍有待确定。